SCHEMBL7180697

SCHEMBL7180697

COc1ccc(PC(=O)c2c(C)cccc2Cl)c(OC)c1.[LiH]

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.41
PTGS2 P35354 1/20 0.41
GAA P10253 1/20 0.41
ABCG2 Q9UNQ0 2/20 0.40
TOP1 P11387 1/20 0.40
ALDH1A1 P00352 4/20 0.40
MAPT P10636 3/20 0.40
LMNA P02545 3/20 0.39
CXCL12 P48061 1/20 0.39
TSHR P16473 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
EGFR P00533 1/20 0.38
FGFR1 P11362 1/20 0.38
HTT P42858 1/20 0.37
S1PR4 O95977 1/20 0.37
RECQL P46063 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL7180704 0.98 KMT2A (0.41) KMT2AMEN1PTGS2GAAABCG2
SCHEMBL7175310 0.94 ABCG2 (0.44) KMT2AMEN1PTGS2ABCG2TOP1
SCHEMBL7181242 0.91 MAPT (0.48) KMT2AMEN1PTGS2GAAABCG2
Lithium SCHEMBL7175318 0.91 ABCG2 (0.44) KMT2AMEN1PTGS2ABCG2TOP1
SCHEMBL7188541 0.91 KMT2A (0.45) KMT2AMEN1GAAABCG2ALDH1A1
SCHEMBL7174928 0.90 MAPT (0.39) KMT2AMEN1PTGS2GAAALDH1A1
Lithium SCHEMBL7181252 0.89 MAPT (0.48) KMT2AMEN1PTGS2GAAABCG2
Lithium SCHEMBL7188548 0.89 KMT2A (0.45) KMT2AMEN1GAAABCG2ALDH1A1
SCHEMBL7182596 0.86 MAPT (0.43) KMT2AMEN1PTGS2GAAABCG2
SCHEMBL7189833 0.86 MAPT (0.41) KMT2AMEN1PTGS2GAATOP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KMT2A 1586/4885MEN1 2312/4885PTGS2 3909/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KMT2A 956/4885MEN1 2263/4885PTGS2 3871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.